Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN4336 · 1 trial · 1 indication
Dose escalation
Dose escalation
Dose escalation
Dose escalation
Dose escalation
Dose escalation
Dose expansion
| Arm | Type | Description |
|---|---|---|
| Module 1- Monotherapy | EXPERIMENTAL | - |
| Module 3-Combo Therapy | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| REGN4336 | DRUG | Administered per the protocol |
| REGN5678 | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Histologically or cytologically confirmed adenocarcinoma of the prostate without pure small cell carcinoma 2. Metastatic, Castration-Resistant Prostate Cancer (mCRPC) with PSA value at screening ≥4 ng/mL and that has progressed within 6 months prior to screening, accordin...
REGN4336 is an investigational small molecule being studied for the treatment of metastatic castration-resistant prostate cancer. It is currently in Phase 1 clinical development and has not been approved by the FDA. The drug is being evaluated alone and in combination with REGN5678 in adult participants with advanced prostate cancer.
REGN4336 targets PSMA, a protein that is commonly expressed on prostate cancer cells. By targeting PSMA, the drug aims to interfere with cancer cell activity. This mechanism is being investigated in a Phase 1 clinical trial for metastatic castration-resistant prostate cancer.
REGN4336 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker REGN. The company is currently conducting a Phase 1 clinical trial to evaluate the safety and efficacy of REGN4336 in patients with advanced prostate cancer.
REGN4336 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is recruiting participants with metastatic castration-resistant prostate cancer to assess the drug's safety and how well it works, both alone and in combination with REGN5678.
REGN4336 is being studied in a Phase 1 clinical trial with the identifier NCT05125016. This trial is recruiting 228 adult male participants with metastatic castration-resistant prostate cancer in the United States. The study is evaluating REGN4336 alone and in combination with REGN5678, and is currently active and recruiting.